Eli Lilly’s Omvoh shows long-term effectiveness against UC, Crohn’s disease

Eli Lilly’s (NYSE:LLY) released study results on Monday that showed the long-term efficacy of mirikizumab, marketed under the brand name Omvoh, against both ulcerative colitis (UC) and Crohn’s disease.

The drugmaker claims Omvoh is the first and only IL23p19 antagonist to report long-term, multi-year, sustained efficacy and safety for the two conditions, based on results from two phase 3 studies in moderately to severely active UC and Crohn’s disease.

In the UC study, 81% of patients maintained long-term clinical remission and 82% achieved long-term endoscopic remission after three years of treatment.

In the Crohn’s disease study, 87% were in clinical remission and 54% of patients were in endoscopic remission.

Omvoh was approved by the U.S. FDA in October 2023 as the first of its class drug to treat UC in adults. It is also approved in 44 countries around the world. Eli Lilly (LLY) has marketing applications ongoing for Crohn’s disease in the U.S., Canada, Europe, Japan and China. Additional global regulatory submissions are planned.

Eli Lilly (LLY) also reported positive one-year data earlier this month from a Phase 3 study that compared its drug to Johnson & Johnson’s (JNJ) Stelara in the treatment of Crohn’s disease.